Share starts trading without unit rights and warrants
The ongoing capital raise would reduce the financing risks and secures the company’s financing until early 2025. We expect the raise to succeed. After short-term funding is in check, SciBase can focus again on executing its growth strategy in US, where clear signs of success could be emerging starting in 2025. We highlight the special situation of the stock due to the very large number of warrants to be issued with the raise.
Scibase Holding
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
Read more on company pageKey Estimate Figures18.04
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 23.2 | 31.9 | 50.4 |
growth-% | 29.94 % | 37.33 % | 57.94 % |
EBIT (adj.) | -53.9 | -56.1 | -46.9 |
EBIT-% (adj.) | -232.04 % | -175.89 % | -93.11 % |
EPS (adj.) | -0.51 | -0.24 | -0.20 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |